Every Form 4 that Oric Pharmaceuticals, Inc. (ORIC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ORIC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORIC filings page.
Oric Pharmaceuticals, Inc. Chief Financial Officer Dominic Piscitelli exercised 14,000 stock options on October 20, 2026, at an exercise price of $4.36 per share, acquiring 14,000 common shares and selling 14,000 shares at a weighted average price of $13.5279 per share. The sale was made under a Rule 10b5-1 trading plan adopted May 26, 2026; sale prices ranged from $13.50 to $13.65. After the exercise, the reported position was 64,500 stock options.
Oric Pharmaceuticals, Inc. director Richard A. Heyman exercised 3,500 options on October 1, 2026, acquiring 3,500 common shares at an exercise price of $1.60 per share. He sold 3,500 directly held shares, and RAHD Capital, LLC sold 3,200 shares held of record by the LLC; Heyman had voting and investment power over the LLC-held shares. Both sales were effected under a Rule 10b5-1 trading plan adopted by Heyman and RAHD Capital, LLC, and were reported at $12.9141 per share, with trade prices ranging from $12.57 to $13.39. The option entry reports 26,700 shares following the exercise.
Oric Pharmaceuticals, Inc. Chief Financial Officer Dominic Piscitelli exercised options to acquire 13,400 common shares on September 28, 2026, at a $4.36 exercise price. He then sold 13,400 shares at a weighted average of $13.5267 per share; the reported sale-price range was $13.50 to $13.575. The sale was made under a Rule 10b5-1 trading plan adopted May 26, 2026. His reported option position after the exercise was 78,500 options.
Oric Pharmaceuticals, Inc. Chief Financial Officer Dominic Piscitelli exercised 600 options on September 24, 2026, at an exercise price of $4.3600 per share, acquiring 600 common shares. On the same date, he sold 100 shares at $13.5000 per share and 500 shares at $13.5050 per share. The sales were made under a Rule 10b5-1 trading plan adopted on May 26, 2026. The option row reports 91,900 shares following the transaction.
Oric Pharmaceuticals, Inc. (ORIC) reported that Chief Financial Officer Dominic Piscitelli exercised stock options and sold shares on August 26, 2026. He exercised options for 52,000 shares of common stock at $4.36 per share and 25,000 shares at $6.00 per share, acquiring a total of 77,000 common shares. On the same date, he sold 77,000 common shares at an average price of $13.6859 per share in transactions effected pursuant to a Rule 10b5-1 trading plan adopted on May 26, 2026. One option grant includes a vesting schedule where 25% vested on February 1, 2024 and the remaining shares vest monthly thereafter. A referenced common stock position includes 1,680 shares acquired under Oric’s 2020 Employee Stock Purchase Plan.
Oric Pharmaceuticals director Richard A. Heyman exercised stock options to acquire 3,500 shares of common stock at $1.6000 per share and on July 24, 2026 sold a total of 13,100 common shares at $12.0200 per share, including 6,100 shares held through RAHD Capital, LLC. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Heyman and RAHD Capital, LLC. After the option exercise, 30,200 options remained outstanding and RAHD Capital, LLC held 206,672 shares over which he has voting and investment power.
Oric Pharmaceuticals director Richard A. Heyman, through an associated entity, reported a small insider sale of Oric Pharmaceuticals, Inc. common stock.
RAHD Capital, LLC, an entity for which Heyman has voting and investment power, sold 300 shares of common stock at $12.00 per share in an open-market transaction on July 6, 2026, executed under a pre-arranged Rule 10b5-1 trading plan. After this sale, RAHD Capital, LLC held 212,772 shares indirectly, while Heyman also reported a separate direct holding entry showing 41,800 shares owned directly.
Oric Pharmaceuticals Chief Financial Officer Dominic Piscitelli reported option exercises and share sales in Oric Pharmaceuticals, Inc. common stock. On February 24, 2026, he exercised stock options for 52,000 shares at an exercise price of $4.36 per share, increasing his common stock holdings before any sale.
On the same date, he then sold 52,000 shares of common stock in open-market transactions at a weighted average price of $13.5132 per share, within a range of $13.50 to $13.53, under a pre-arranged Rule 10b5-1 trading plan adopted on June 24, 2025. Following these transactions, he directly owned 68,148 shares of Oric Pharmaceuticals common stock.
Oric Pharmaceuticals director Richard A. Heyman reported planned stock sales under a Rule 10b5-1 trading plan shared with RAHD Capital, LLC. On January 16, 2026, he sold 3,500 shares of common stock directly at a weighted average price of $12.0046, leaving 41,800 shares held directly. The same day, 3,200 additional shares were sold indirectly at the same weighted average price, with 213,072 shares then held of record by RAHD Capital, LLC, over which he has voting and investment power. In total, the filing notes a weighted average price for 6,700 shares sold in a price range of $12.00 to $12.03.
Oric Pharmaceuticals director files insider transaction report for new stock options. Director Lori Anne Kunkel reported receiving a stock option covering 40,000 shares of Oric Pharmaceuticals common stock on January 2, 2026. The option has an exercise price of $8.17 per share and is held as a derivative security with direct ownership. According to the vesting terms, 1/12 of the shares subject to the option vest on each monthly anniversary of January 2, 2026, resulting in full vesting over one year. The option is scheduled to expire on January 1, 2036, if not exercised earlier.
Oric Pharmaceuticals director Steven L. Hoerter reported a new stock option grant for 40,000 shares of common stock. The option, with an exercise price of $8.17 per share, was awarded on January 2, 2026 and is held directly. It is scheduled to vest in equal monthly installments, with 1/12 of the shares vesting on each one-month anniversary of January 2, 2026, until fully vested. The option expires on January 1, 2036, giving the director a long-dated right to purchase Oric common shares at the fixed exercise price.
Oric Pharmaceuticals, Inc. director Richard A. Heyman reported receiving a stock option grant for 40,000 shares of common stock. The option has an exercise price of $8.17 per share and expires on January 1, 2036. According to the vesting schedule, 1/12 of the shares under the option vest on each monthly anniversary of January 2, 2026, resulting in full vesting over one year. Following this grant, he beneficially owns 40,000 stock options directly.
Oric Pharmaceuticals Chief Financial Officer Dominic Piscitelli reported new equity awards. On January 2, 2026, he received a stock option covering 206,500 shares of Oric common stock with an exercise price of $8.17 per share. According to the vesting terms, 25% of these option shares vest on January 2, 2027, and the remaining shares vest in equal monthly installments over the following 36 months.
He was also granted 34,500 restricted stock units (RSUs), each representing a right to receive one share of Oric common stock. One-third of these RSUs vests on each of December 15, 2026, December 15, 2027, and December 15, 2028. Both the option and RSUs are reported as directly owned and were acquired as part of his compensation.
Oric Pharmaceuticals Chief Medical Officer Pratik S. Multani received new equity awards in the form of stock options and restricted stock units. On January 2, 2026, he was granted stock options covering 214,000 shares of Oric common stock at an exercise price of $8.17 per share. According to the vesting schedule, 25% of these options will vest on January 2, 2027, with the remaining options vesting in equal monthly installments over the following 36 months.
He was also granted 35,500 restricted stock units, each representing a contingent right to receive one share of Oric common stock. One-third of these RSUs will vest on each of December 15, 2026, December 15, 2027, and December 15, 2028, subject to the award terms. All reported holdings are listed as directly owned.
Oric Pharmaceuticals, Inc. insider equity activity shows its Chief Medical Officer reporting routine stock transactions. On December 15, 2025, the officer acquired 29,333 shares of Oric common stock at $0 through the vesting and settlement of restricted stock units (RSUs). The filing states that each RSU represents a right to receive one share of common stock.
On December 16, 2025, the officer sold 10,720 shares of common stock at a weighted average price of $9.0605 per share to cover tax withholding obligations tied to the RSU vesting, described as not a discretionary sale. After these transactions, the officer beneficially owned 68,149 shares of Oric common stock, including 2,771 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Oric Pharmaceuticals, Inc. reported insider equity activity by its Chief Financial Officer. On 12/15/2025, the CFO acquired 29,333 shares of common stock at an exercise price of $0 through the settlement of restricted stock units (RSUs), increasing direct beneficial ownership to 78,868 shares.
On 12/16/2025, the CFO sold 10,720 shares of common stock at a weighted average price of $9.0604 per share, leaving 68,148 shares owned directly. The sale was made solely to cover tax withholding obligations related to RSU vesting. The holdings include 1,218 shares acquired under the company’s 2020 Employee Stock Purchase Plan, and remaining RSUs continue to vest in equal annual installments each December 15 from 2025 through 2027.
Oric Pharmaceuticals, Inc. reported an equity transaction by its President and CEO, who is also a director. On December 15, 2025, the executive acquired 83,666 shares of common stock at $0 upon the vesting and settlement of restricted stock units (RSUs). On December 16, 2025, 33,374 shares of common stock were sold at a weighted average price of $9.06 to cover tax withholding obligations related to the RSU vesting, described as a non-discretionary sale. Following these transactions, the executive beneficially owned 581,711 shares of Oric common stock directly, with additional RSUs remaining subject to vesting over future dates.